Genotyping of human papillomavirus in triaging of low-grade cervical cytology - 03/08/11
Résumé |
Objective |
The objective of the study was to evaluate whether typing of human papillomavirus (HPV) among women with low-grade cervical cytology can improve the ability to identify women with cervical cancer or cervical intraepithelial neoplasia grade III (CIN III or worse).
Study Design |
A total of 1595 women with low-grade cervical cytology participating in a randomized implementation trial of HPV triaging using Hybrid Capture II were also HPV genotyped and CIN III or worse predictive values evaluated.
Results |
HPV 16 was detected in 57% of cases with CIN III or worse but only among 24% of all tested women. Testing for the 3 HPV types with highest risk (HPV16/31/33) detected 77% of CIN III or worse, with 36% of women testing positive. Positivity for the other high-risk HPV types had a decreased risk for CIN III or worse.
Conclusion |
Different high-risk HPV types confer different risks for the presence of CIN III or worse, implying that HPV genotyping could be useful for the optimization of triaging strategies.
Le texte complet de cet article est disponible en PDF.Key words : human papillomavirus genotyping, low-grade cervical cytology, triaging
Plan
| This study was supported in part by the Swedish Cancer Society. |
|
| Reprints not available from the authors. |
|
| Cite this article as: Söderlund-Strand A, Eklund C, Kemetli L, et al. Genotyping of human papillomavirus in triaging of low-grade cervical cytology. Am J Obstet Gynecol 2011;205:145.e1-6. |
Vol 205 - N° 2
P. 145.e1-145.e6 - août 2011 Retour au numéro
Article précédent
- Adverse events associated with laparoscopy vs laparotomy in the treatment of endometrial cancer
- Jason C. Barnett, Laura J. Havrilesky, Amy E. Bondurant, Nicole D. Fleming, Paula S. Lee, Angeles Alvarez Secord, Andrew Berchuck, Fidel A. Valea
- Exenteration as a primary treatment for locally advanced cervical cancer: long-term results and prognostic factors
- Dirk Michael Forner, Bjoern Lampe
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?